Intellia Therapeutics, Inc. Profile Avatar - Palmy Investing

Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the …
Biotechnology
US, Cambridge [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

Searching for a Dividend Aristocrat? Sign Up to view the entire dividend history of Intellia Therapeutics, Inc.

Growth Rates
0.00% YoY
0.00% 3Yr
0.00% 5Yr
0.00% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
- -% Yield
0.00% Payout Ratio
End of NTLA's Analysis
CIK: 1652130 CUSIP: 45826J105 ISIN: US45826J1051 LEI: - UEI: -
Secondary Listings
NTLA has no secondary listings inside our databases.